Furiex Pharmaceuticals, Inc. (FURX)
-NasdaqGS 38.13 
1.38(3.76%) 18 May 04:00 SGT|After Hours
:
38.13 0.00 (0.00%) 18 May 04:32 SGT
| Prev Close: | 36.75 |
|---|
| Open: | 36.64 |
|---|
| Bid: | 34.75 x 200 |
|---|
| Ask: | 39.98 x 100 |
|---|
| 1y Target Est: | 52.00 |
|---|
| Beta: | 0.994 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 36.16 - 39.45 |
|---|
| 52wk Range: | 15.28 - 42.30 |
|---|
| Volume: | 339,574 |
|---|
| Avg Vol (3m): | 79,065 |
|---|
| Market Cap: | 385.65M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.42 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- FURIEX PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Sat, 18 May)
- 5 Healthcare Stock Earnings Snapshotsat Wall St. Cheat Sheet(Mon, 13 May)
- Narrower-than-Expected Loss at ArQuleZacks(Fri, 10 May)
- FURIEX PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, 9 May)
- Furiex Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, 9 May)
- Furiex Pharmaceuticals Earnings: Here’s Why Investors are Not Happy Nowat Wall St. Cheat Sheet(Wed, 8 May)
- Furiex Reports First Quarter 2013 Financial ResultsBusiness Wire(Wed, 8 May)
- Furiex Pharmaceuticals: Here’s What Investors Need to Know Before Earningsat Wall St. Cheat Sheet(Tue, 7 May)
- FURIEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Tue, 7 May)
- Q1 2013 Furiex Pharmaceuticals Inc Earnings Release - After Market CloseCCBN(Tue, 7 May)
Key Statistics
| Forward P/E (1 yr): | 69.33 |
|---|
| P/S (ttm): | 4.82 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.54 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -1.28 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | -0.18 |
|---|
Business Summary
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by ...
View More